Singapore’s IP Office to Grant MilliporeSigma’s Patent Application for CRISPR Technology – Markets Insider
|
Singapore’s IP Office to Grant MilliporeSigma’s Patent Application for CRISPR Technology
Markets Insider BURLINGTON, Mass., Dec. 19, 2017 /CNW/ — MilliporeSigma, a leader in genome editing, today announced that the Intellectual Property Office of Singapore has issued a “Notice of Eligibility for Grant” for MilliporeSigma’s patent application covering the … Singapore’s IP Office to Grant Merck’s Patent Application for CRISPR …PR Newswire UK (press release) |
|
Singapore’s IP Office to Grant Merck’s Patent Application for CRISPR Technology
Markets Insider This forthcoming, fundamental patent in Singapore, entitled “CRISPR-BASED GENOME MODIFICATION AND REGULATION,” covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion … |
BioPharma-Reporter.com |
Takeda’s off-the-shelf stem cell therapy closes in on EU approval
BioPharma-Reporter.com The EMA has recommended approval of the first ever off-the-shelf stem cell therapy, Takeda and Tigenix’s Alofisel (darvadstrocel). The European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorisation of the candidate … Is Buying All-time Stock Like TiGenix NV (TIG) a Winning Strategy?Frisco Fastball |
|
Stem cell expert named as Medical Research Council head
Times Higher Education (THE) Professor Watt is a world-renowned expert on the skin’s stem cells. She is currently the director of the Centre for Stem Cells and Regenerative Medicine at Kings College London and leads a team of 80 researchers. Professor Watt said: “I am deeply … |
KAGS News |
Immunotherapy closing in on a cure for cancer
KAGS News It’s no secret, Kentucky leads the nation in lung cancer deaths as a tobacco-rich state with a high rate of radon and pollution. In the Bluegrass, more than 4,800 people are diagnosed with lung cancer every year and until recently, more than half would … |
|
Fed. Circ. Upholds Genzyme’s Win In Stem Cell Patent Case
Law360 Law360, New York (December 18, 2017, 7:04 PM EST) — The Federal Circuit on Monday affirmed a Delaware federal judge’s finding in a bench trial that a Genzyme Corp. patent on harvesting stem cells is valid, leaving in place a ruling that barred generic … |